DeFinium Therapeutics Inc (DFTX)

$20.68 +0.08 (0.39%)
Market Cap 2.06B
Revenue (ttm) 0.00
Net Income (ttm) -183.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 1,957,700
Avg Vol 1,705,360
Day's Range N/A - N/A
Shares Out 99.70M
Stochastic %K 90%
Beta 2.44
Analysts Strong Sell
Price Target $34.14

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
Source206
Source206 Apr. 5 at 3:34 PM
$DFTX
0 · Reply
terrapin22
terrapin22 Apr. 3 at 2:25 AM
$DFTX
1 · Reply
LoadedUP1000
LoadedUP1000 Apr. 2 at 11:30 PM
$ATAI $CMPS $DFTX $GHRS $HELP Exactly!!! I think most people missed this news. Locked and loaded!
0 · Reply
brunoq14
brunoq14 Apr. 2 at 10:14 PM
$DFTX I guess people figure that if a company got BTD because of excellent results in a Phase 2 GAD trial, they are a good bet to not screw up Phase 3.
1 · Reply
a_rational_investor
a_rational_investor Apr. 2 at 9:31 PM
$DFTX
0 · Reply
Sailingsoon
Sailingsoon Apr. 2 at 4:53 PM
$DFTX 21 in the making ?
0 · Reply
BobbyCucumber
BobbyCucumber Apr. 2 at 3:58 PM
$DFTX
0 · Reply
Horseman23
Horseman23 Apr. 2 at 3:13 PM
$DFTX
0 · Reply
quandrypeaks
quandrypeaks Apr. 2 at 2:49 PM
$DFTX what happened to this stock recently. my average has somehow increased significantly since I bought a few years ago .. was there a split or something?
2 · Reply
Rocketzz
Rocketzz Apr. 2 at 2:27 PM
$DFTX
0 · Reply
Latest News on DFTX
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Mar 31, 2026, 7:00 AM EDT - 5 days ago

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Definium Therapeutics Announces New Employee Inducement Grants

Mar 30, 2026, 4:01 PM EDT - 5 days ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Mar 26, 2026, 7:00 AM EDT - 10 days ago

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 9:57 PM EST - 5 weeks ago

Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Feb 26, 2026, 4:01 PM EST - 5 weeks ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Definium Therapeutics to Participate at Upcoming Investor Conferences

Feb 24, 2026, 7:01 AM EST - 5 weeks ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Feb 19, 2026, 4:01 PM EST - 6 weeks ago

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 29, 2026, 7:00 AM EST - 2 months ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 20, 2026, 7:00 AM EST - 2 months ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 7:16 PM EST - 2 months ago

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MMED

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 13, 2026, 7:00 AM EST - 2 months ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Jan 12, 2026, 7:00 AM EST - 2 months ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:01 AM EST - 3 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

MindMed Announces New Employee Inducement Grant

Dec 15, 2025, 4:01 PM EST - 3 months ago

MindMed Announces New Employee Inducement Grant

MindMed Announces New Employee Inducement Grants

Dec 1, 2025, 4:01 PM EST - 4 months ago

MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:46 PM EST - 5 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 5 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 5 months ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 5 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 5 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 6 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 6 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 7 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 7 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 7 months ago

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 8 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 9 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 11 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 11 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 11 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 11 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 11 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 1 year ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Source206
Source206 Apr. 5 at 3:34 PM
$DFTX
0 · Reply
terrapin22
terrapin22 Apr. 3 at 2:25 AM
$DFTX
1 · Reply
LoadedUP1000
LoadedUP1000 Apr. 2 at 11:30 PM
$ATAI $CMPS $DFTX $GHRS $HELP Exactly!!! I think most people missed this news. Locked and loaded!
0 · Reply
brunoq14
brunoq14 Apr. 2 at 10:14 PM
$DFTX I guess people figure that if a company got BTD because of excellent results in a Phase 2 GAD trial, they are a good bet to not screw up Phase 3.
1 · Reply
a_rational_investor
a_rational_investor Apr. 2 at 9:31 PM
$DFTX
0 · Reply
Sailingsoon
Sailingsoon Apr. 2 at 4:53 PM
$DFTX 21 in the making ?
0 · Reply
BobbyCucumber
BobbyCucumber Apr. 2 at 3:58 PM
$DFTX
0 · Reply
Horseman23
Horseman23 Apr. 2 at 3:13 PM
$DFTX
0 · Reply
quandrypeaks
quandrypeaks Apr. 2 at 2:49 PM
$DFTX what happened to this stock recently. my average has somehow increased significantly since I bought a few years ago .. was there a split or something?
2 · Reply
Rocketzz
Rocketzz Apr. 2 at 2:27 PM
$DFTX
0 · Reply
goral17
goral17 Apr. 2 at 1:35 PM
$DFTX PRINTING! this one here? It will roll over... Just a matter of time 😉
1 · Reply
prismmarketview
prismmarketview Apr. 2 at 1:33 PM
Today, on World Autism Awareness Day 2026, we celebrate the brilliance and individuality of people on the autism spectrum while recognizing companies driving innovation to support them. 💙 SciSparc Ltd. ( $SPRC) is advancing its SCI-210 clinical trial exploring a proprietary CBD + PEA therapy for pediatric ASD. Definium Therapeutics (NASDAQ: $DFTX) is developing DT402 as a potential treatment for the core symptoms of Autism Spectrum Disorder (ASD). These efforts reflect meaningful progress across the NASDAQ and NASDAQ CM, where science, inclusion, and compassion meet to improve lives. #worldautismawarenessday #autismawareness #inclusionmatters #sprc #dftx #nasdaq @SciSparc prismmarketview.com/compani... @definiumtx prismmarketview.com/compani...
0 · Reply
goral17
goral17 Apr. 2 at 3:05 AM
$DFTX Markets are shaky again... Dftx has been resilient in the past... Let's see if it happens again. 🤷🏾
0 · Reply
ngalifi1
ngalifi1 Apr. 2 at 1:15 AM
$DFTX just block goral, why do you guys still entertain him lol
2 · Reply
Jackie_O_
Jackie_O_ Apr. 2 at 12:10 AM
$DFTX Looking good 😊
0 · Reply
zcurrency
zcurrency Apr. 1 at 8:36 PM
$DFTX remember it does the opposite
0 · Reply
Kimjonguun
Kimjonguun Apr. 1 at 8:02 PM
$DFTX This has broken through all time high today and will keep going after today's Joe Rogan podcast and RFK backing these therapies.
3 · Reply
Chukt22
Chukt22 Apr. 1 at 7:49 PM
$DFTX 60->75
0 · Reply
goral17
goral17 Apr. 1 at 6:41 PM
$DFTX War. Oil. Inflation. Trump!
1 · Reply
Bbbb44444
Bbbb44444 Apr. 1 at 6:21 PM
$DFTX Overbought, take those profits.
3 · Reply
goral17
goral17 Apr. 1 at 6:04 PM
$DFTX 😎 I think the top is in?
2 · Reply
Sailingsoon
Sailingsoon Apr. 1 at 5:51 PM
$DFTX
0 · Reply